Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: March 12, 2018
Context: The filing announces a registered direct offering of American Depositary Shares (ADSs) and warrants to institutional investors to raise capital.
Key Financial Metrics and Transaction Details
| Metric | Value |
|---|---|
| Gross Proceeds | Approximately $5,000,000 |
| ADSs Issued | 3,333,336 |
| Offering Price | $1.50 per ADS |
| Warrants Issued | 2,500,002 (to purchase ADSs) |
| Warrant Exercise Price | $2.00 per ADS |
| Warrant Term | 5.5 years (exercisable after 6 months) |
| Placement Agent Fee | 6% of aggregate purchase price plus $50,000 expense allowance |
| Placement Agent Warrants | 5% of aggregate ADSs sold |
Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these operational financial metrics. The document focuses exclusively on the terms of the capital raise.
Material Changes and Transaction Terms
- Closing Date: Expected on or about March 13, 2018, subject to customary closing conditions.
- Lock-Up Period: The Company agreed not to issue or announce the issuance of ADSs, ordinary shares, or equivalents for 90 days following the closing.
- Variable Rate Restriction: The Company is restricted from entering into "variable rate transactions" for 13 months following the closing.
- Warrant Exercise: Warrants may be exercised on a cashless basis if no effective registration statement exists for the underlying ADSs six months after issuance.
Guidance, Risks, and Contingencies
- Forward-Looking Statements: The filing contains forward-looking statements regarding the expected closing date. Management notes that the closing is subject to conditions and contingencies; if not satisfied, the offering may not close.
- Regulatory Status: The warrants and underlying ADSs are sold pursuant to exemptions from registration (Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D) and are not registered under the Securities Act of 1933.
- Investor Qualifications: Investors represented they are accredited investors or qualified institutional buyers.
Key Facts for Investor Verification
- Verify the actual closing of the offering on or about March 13, 2018, as it is subject to customary conditions.
- Confirm the dilution impact of the 3,333,336 new ADSs and the potential future dilution from 2,500,002 warrants.
- Review the use of proceeds, which is not explicitly detailed in this specific filing text.
- Monitor the 90-day lock-up period and 13-month variable rate transaction restriction for future capital raising activities.